Advanced glycation end-products: A common pathway in diabetes and age-related erectile dysfunction

Free Radical Research

Volumn 47, Issue S1, 2013, Pages 49-69

  Neves, D ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Advanced glycation end products; Aging; Corpus cavernosum; Diabetes; Erectile dysfunction; Nitric oxide

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANTIHYPERTENSIVE AGENT; CARNITINE; CHELATING AGENT; COCARBOXYLASE; CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPHENOL; PYRIDOXAMINE; RAMIPRIL; SCLEROPROTEIN; SILDENAFIL; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VARDENAFIL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

AGING; ALCOHOL CONSUMPTION; ALTERNATIVE RNA SPLICING; ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD VESSEL COMPLIANCE; BODY WEIGHT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL (TOPIC); CORPUS CAVERNOSUM; DIABETES MELLITUS; DIET SUPPLEMENTATION; ELASTICITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME SYNTHESIS; ERECTILE DYSFUNCTION; EXERCISE; EXTRACELLULAR MATRIX; GLUCOSE TRANSPORT; GLYCATION; HIGH RISK PATIENT; HUMAN; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SIDE EFFECT; SMOKING; VASODILATATION;

AGING; DIABETES MELLITUS; ERECTILE DYSFUNCTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; NITRIC OXIDE; PENIS; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84881239565     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.821701     Document Type: Review

References (260)

1. N , Oliveira R , Tomada I , Vendeira P , Neves D. Comparative ultrastructural study of human corpus cavernosum during ageing. Microsc Microanal 2008; 14: S3152-S3155.
2. Cordeiro AL , Figueiredo A , Godinho F , Martins I , Vendeira P , Almeida H, Neves D. Ultrastructural characterization of corpus cavernosum of ageing, orchidectomy and diabetes rat experimental models. Microsc Microanal 2008;14:S397-S398.
3. Burnett AL , Nelson RJ , Calvin DC , Liu JX , Demas GE , Klein SL , et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996;2:288-296.
4. Hurt KJ , Sezen SF , Lagoda GF , Musicki B , Rameau GA , Snyder SH , Burnett AL. Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2012;109:16624-16629.
5. Ignarro LJ , Bush PA , Buga GM , Wood KS , Fukuto JM , Rajfer J. Nitric oxide and cyclic GMP formation upon electrical fi eld stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;31:843-850.
6. Kaya C , Uslu Z , Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006;18:55-60.
7. Shamloul R , Ghanem H. Erectile dysfunction. 2013;381:153-165.
8. Goldstein I. The association of ED (erectile dysfunction) with ED (endothelium dysfunction) in the international journal of impotence research: The journal of sexual medicine. Int J Impot Res 2003; 15: 229-230.
9. Guay AT. ED2: erectile dysfunction-endothelial dysfunction. Endocrinol Metabol Clin N Am 2007;36:453-463.
10. Ayta IA , Mckinlay JB , Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56.
11. Feldman HA , Goldstein I , Hatzichristou DG , Krane RJ , McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
12. Ghalayini IF , Al-Ghazo MA , Al-Azab R , Bani-Hani I , Matani YS , Barham AE, et al. Erectile dysfunction in a Mediterranean country: Results of an epidemiological survey of a representative sample of men. Int J Impot Res 2010;22:196-203.
13. Ponholzer A , Temml C , Mock K , Marzlaekm M , Obermayr R, Maderbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-86.
14. Thorve VS , Kshirsagar AD , Vyawahare NS , Joshi VS , Ingale KG , Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 2011; 25: 129-136.
15. Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 1996;28:209-216.
16. Shaeer O , Shaeer K. The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: Erectile Dysfunction Among English-Speakers. J Sex Med. 2012 [Epub ahead of print].
17. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
18. Cheitlin CMD. Erectile dysfunction: the earliest sign of generalized vascular disease? J Am Coll Cardiol 2004;43:185-186.
19. Stadtman ER. Protein oxidation and aging. Science 1992;257:1220-1224.
20. Bonnefont-Rousselot D , Bastard JP , Jaudon MC , Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163-176.
21. Silva FH , Mnica FZ , Bu FR , Brugnerotto AF , Priviero FB , Toque HA , Antunes E. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-gged rats: prevention by antioxidant therapy. J Sex Med 2013 [Epub ahead of print].
22. Figueiredo A , Cordeiro AL , Tomada N , Tomada I , Rodrigues A, Gouveia A, Neves D. Real-time PCR study of Ang1, Ang2, Tie-2, VEGF and KDR expression in human erectile tissue during aging. J Sex Med 2011;8:1341-1351.
23. Tomada N , Tomada I , Vendeira P , Cruz F , Neves D. Characterization of VEGF and Angiopoietins expression in human corpus cavernosum during aging. J Sex Med 2011;7:1410-1418.
24. Baraibar MA , Liu L , Ahmed EK , Friguet B. Protein oxidative damage at the crossroads of cellular senescence, aging and aging-related diseases. Oxid Med Cell Longev 2012 [Epub ahead of print].
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
26. Vlassara H , Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 2004; 5: 181-188.
27. Mohamed AK , Bierhaus A , Schiekofer S , Tritschler H , Ziegler R , Nawroth PP. The role of oxidative stress and NFkappaB activation in late diabetic complications. Biofactors 1999;10:157-167.
28. Higashi Y , Noma K , Yoshizumi M , Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009;73:411-418.
29. Seftel AD , Vaziri ND , Ni Z , Razmjouei K , Fogarty J , Hampel N , et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible Effect through iNOS or eNOS. Urology 1997;50:1016-1026.
30. Cartledge JJ , Eardley I , Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001;87:402-407.
31. Jakus V , Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004;53:131-142.
32. Jiaan DB , Seftel AD , Fogarty J , Hampel N , Cruz W , Pomerantz J , et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995; 13: 369-375.
33. Hipkiss AR. Accumulation of altered proteins and ageing: causes and Effects. Expt Gerontolol 2006; 41: 464-473.
34. Schneich C. Protein modifi cation in aging: an update. Exp Gerontol 2006; 41807-41812.
35. Maillard LC. Action des acides amines sur les sucres: formation des mlanoides par voie mthodique. C R Acad Sci 1912;154:66-68.
36. Ahem N , Thornally PJ. Advanced glycation end-products: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-245.
37. Rabbani N , Thornalley PJ. Glycation research in aminoacids: a place to call home. Aminoacids 2012;42:1087-1096.
38. Sell DR , Monnier VM. Molecular basis of arterial stiff ening: role of glycation-A mini-review. Gerontology 2012; 58: 227-237.
39. Lyons T , Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a carbonyl stress hypothesis. Diabetes Rev 1997;5:365-391.
40. Degenhardt TP, Thorpe SR , Baynes JW. Chemical modifi cation of proteins by methylglyoxal. Cell Mol Biol 1998;44:1139-1145.
41. Xue M , Rabbani N , Thornalley PJ. Glyoxalase in ageing. Sem Cell Dev Biol 2011;22:293-301.
42. He C , Sabol J , Mitsuhashi T , Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308-1315.
43. Bucala R , Makita Z , Vega G , Grundy S , Koschinsky T , Cerami A, Vlassara H. Modifi cation of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insuffi ciency. Proc Natl Acad Sci USA 1994;91:9441-9445.
44. Makita Z , Vlassara H , Rayfi eld E , Cartwright K , Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651-653.
45. Peyroux J , Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie 2006;54:405-419.
46. Baumann M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J Am Soc Hypertens 2012;6:427-435.
47. Mizutari K , Ono T , Ikeda K , Kayashima K , Horiuchi S. Photo-enhanced modifi cation of human skin elastin in actinic elastosis by N(epsilon)- (carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol 1997;108:797-802.
48. Haitoglou CS , Tsilibary EC , Brownlee M , Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992;267:12404-12407.
49. Thomas MC , Baynes JW , Thorpe SR , Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005;6:453-474.
50. Knott HM , Brown BE , Davies MJ , Dean RT. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modifi ed and oxidized particles. Eur J Biochem 2003;270:3572-3582.
51. Harja E , Bu DX , Hudson BI , Chang JS , Shen X , Hallam K , et al. Vascular and infl ammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008;118:183-194.
52. Kirstein M , Brett J , Radoff S , Ogawa S , Stern D , Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-9014.
53. Nam MH , Lee HS , Seomun Y , Lee Y , Lee KW. Monocyteendothelium-smooth muscle cell interaction in co-culture: proliferation and cytokine productions in response to advanced glycation end products. Biochim Biophys Acta 2011;1810:907-912.
54. Kirstein M , Aston C , Hintz R , Vlassara H. Receptor-specifi c induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modifi ed proteins. J Clin Invest 1992;90:439-446.
55. Corra-Giannella ML , de Azevedo MR , Leroith D , Giannella-Neto D. Fibronectin glycation increases IGF-I induced proliferation of human aortic smooth muscle cells. Diabetol Metab Syndr 2012; 4: 19.
56. Cantero AV , Portero-Otin M , Ayala V , Auge N , Sanson M , Elbaz M, et al. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 2007;21:3096-3106.
57. Nass N , Vogel K , Hofmann B , Presek P , Silber RE , Simm A. Glycation of PDGF results in decreased biological activity. Int J Biochem Cell Biol 2010;42:749-754.
58. Yang SJ , Chen CY , Chang GD , Wen HC , Chen CY , Chang SC , et al. Activation of Akt by advanced glycation end products (AGEs): involvement of IGF-1 receptor and caveolin-1. PLoS One 2013;8:e58100.
59. Forbes JM , Soulis T , Thallas V , Panagiotopoulos S , Long DM , Vasan S , et al. Renoprotective Effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-114.
60. Christ M , Bauersachs J , Liebetrau C , Heck M , Gnther A , Wehling M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002;51:2648-2652.
61. Su J , Lucchesi PA , Gonzalez-Villalobos RA , Palen DI , Rezk BM, Suzuki Y , et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008;28:1432-1438.
62. Bucala R , Tracey KJ , Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-438.
63. Sena CM , Matafome P , Crisstomo J , Rodrigues L , Fernandes R, Pereira P , Sei? RM. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res 2012;65:497-506.
64. Xu B , Ji Y , Yao K , Cao YX , Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond) 2005;10:439-446.
65. Lai YL , Aoyama S , Nagai R , Miyoshi N , Ohshima H. Inhibition of L-Arginine metabolizing enzymes by L-Arginine-derived advanced glycation end products. J Clin Biochem Nutr 2010;46:177-185.
66. Quehenberger P , Bierhaus A , Fasching P , Muellner C , Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000;49:1561-1570.
67. Giuseppe C , Ferdinando F , Ciro I , Vincenzo M. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006;111:400-423.
68. Aversa A , Basciani S , Visca P , Arizzi M , Gnessi L , Frajese G, Fabbri A. Platelet-derived growth factor (PDGF) and PDGF receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. J Endocrinol 2001;170:395-402.
69. Vlassara H. The AGE-receptor in the in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443.
70. Lu C , He JC , Cai W , Liu H , Zhu L , Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the infl ammatory response to AGE in mesangial cells. Proc Nat Acad Sci 2004;101:11767-11772.
71. Cai W , Torreggiani M , Zhu L , Chen X , He JC , Striker GE , Vlassara H. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2010;298:C624-C634.
72. Cai W , Ramdas M , Zhu L , Chen X , Striker GE , Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA. 2012; 109: 15888-15893.
73. Tomada I , Tomada N , Almeida H , Neves D. Androgen depletion in humans leads to cavernous tissue reorganization and upregulation of Sirt1-eNOS axis. AGE 2013;35:35-47.
74. Vlassara H , Li YM , Imani F , Wojciechowicz D , Yang Z , Liu FT , Cerami A. Identifi cation of galectin-3 as a highaffi nity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-646.
75. Pang J , Rhodes DH , Pini M , Akasheh RT , Castellanos KJ , Cabay RJ, et al. Increased adiposity, dysregulated glucose metabolism and systemic Inflammation in Galectin-3 KO mice. PLoS One 2013;8:e57915.
76. Darrow AL , Shohet RV , Maresh JG. Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics 2011;43:1144-1152.
77. Seki N , Hashimoto N , Sano H , Horiuchi S , Yagui K , Makino H, Saito Y. Mechanisms involved in the stimulatory Effect of advanced glycation end products on growth of rat aortic smooth muscle cells. M etabolism 2 003; 5 2: 1 558-1 563.
78. Calvier L , Miana M , Reboul P , Cachofeiro V , Martinez-Martinez E , de Boer RA , et al. Galectin-3 mediates aldosterone-induced vascular fi brosis. Arterioscler Thromb Vasc Biol 2013;33:67-75.
79. Mackinnon AC , Liu X , Hadoke PW , Miller MR , Newby DE , Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-defi cient mice. Glycobiology 2013;23:654-663.
80. de Boer RA , van Veldhuisen DJ , Gansevoort RT , Muller Kobold AC , van Gilst WH , Hillege HL , et al. The fi brosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55-64.
81. Ohgami N , Nagai R , Ikemoto M , Arai H , Kuniyasu A , Horiuchi S , Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001;276:3195-3202.
82. Araki N , Higashi T , Mori T , Shibayama R , Kawabe Y , Kodama T , et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995;230:408-415.
83. Ramasamy R , Yan SF , Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2012;42:1151-1161.
84. Neeper M , Schmidt AM , Brett J , Yan SD , Wang F , Pan YC , et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-15004.
85. Hofmann MA , Drury S , Fu C , Qu W , Taguchi A , Lu Y , et al. RAGE mediates a novel proinfl ammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
86. Bucciarelli LG , Wendt T , Rong L , Lalla E , Hofmann MA , Goova MT , et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-1128.
87. Hallam KM , Li Q , Ananthakrishnan R , Kalea A , Zou YS , Vedantham S , et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010;5:776-784.
88. Myint KM , Yamamoto Y , Doi T , Kato I , Harashima A , Yonekura H , et al. RAGE control of diabetic nephropathy in a mouse model: Effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-2522.
89. Sorci G , Riuzzi, Giambanco I , Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013;1833:101-109.
90. Mahajan N , Malik N , Bahl A , Dhawan V. Receptor for advanced glycation end products (RAGE) and its infl ammatory ligand EN-RAGE in non-diabetic subjects with premature coronary artery disease. Atherosclerosis 2009;207:597-602.
91. Sun L , Ishida T , Yasuda T , Kojima Y , Honjo T , Yamamoto Y , et al. RAGE mediates oxidized LDL-induced pro-infl ammatory Effects and atherosclerosis in non-diabetic LDL receptor-defi cient mice. Cardiovasc Res 2009; 82: 371-381.
92. Lal MA , Brismar H , Eklf AC , Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002;61:2006-2014.
93. Wautier MP , Chappey O , Corda S , Stern DM , Schmidt AM , Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-E694.
94. Barlovic DP , Soro-Paavonen A , Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 2011;121:43-55.
95. Hall G , Hasday JD , Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580-591.
96. Valencia JV , Mone M , Koehne C , Rediske J , Hughes TE. Binding of receptor for advanced glycation end products (RAGE) ligands is not suffi cient to induce infl ammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 2004; 47: 844-852.
97. Lieuw-A-Fa ML , Schalkwijk CG , Engelse M , van Hinsbergh VW. Interaction of Nepsilon(carboxymethyl) lysine-And methylglyoxal-modifi ed albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 2006;95:320-328.
98. Ptzsch S , Blankenhorn A , Navarrete Santos A , Silber RE , Somoza V , Simm A. The Effect of an AGE-rich dietary extract on the activation of NF-?B depends on the cell model used. Food Funct 2013 [Epub ahead of print].
99. Neves D , Assun?o M , Marques F , Andrade JP , Almeida H. Does regular consumption of green tea Influence VEGF and its receptors expression in aged rat erectile tissue? Possible implications in vasculogenic erectile dysfunction progression. AGE 2008;30:217-228.
100. Higashi T , Sano H , Saishoji T , Ikeda K , Jinnouchi Y , Kanzaki T , et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997;46:463-472.
101. Kalea AZ , Reiniger N , Yang H , Arriero M , Schmidt AM , Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009;23:1766-1774.
102. Yonekura H , Yamamoto Y , Sakurai S , Petrova RG , Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.
103. Choi KM , Yoo HJ , Kim HY , Lee KW , Seo JA , Kim SG , et al. Association between endogenous secretory RAGE, infl ammatory markers and arterial stiff ness. Int J Cardiol 2009 , 132:96-101.
104. Bucciarelli LG , Wendt T , Qu W , Lu Y , Lalla E , Rong LL , et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-2835.
105. Kislinger T , Tanji N , Wendt T , Qu W , Lu Y , Ferran LJ Jr, et al. Receptor for advanced glycation end products mediates Inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001;21:905-910.
106. Colhoun HM , Betteridge DJ , Durrington P , Hitman G , Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011;60:2379-2385.
107. Koyama H , Shoji T , Yokoyama H , Motoyama K , Mori K , Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-2593.
108. Emanuele E , Bertona M. Endogenous secretory RAGE as a potential biochemical screening tool for erectile dysfunction. Med Hypotheses 2006;67:668-669.
109. Semba RD , Ang A , Talegawkar S , Crasto C , Dalal M , Jardack P , et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr 2012;66:3-9.
110. Uribarri J , Cai W , Peppa M , Goodman S , Ferrucci L , Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to infl ammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427-433.
111. Uribarri J , Cai W , Sandu O , Peppa M , Goldberg T , Vlassara H. Diet-derived advanced glycation end products are major contributors to the body ' s AGE pool and induce Inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-466.
112. Gugliucci A , Kotani K , Taing J , Matsuoka Y , Sano Y , Yoshimura M , et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009;54:197-201.
113. Tomada I , Tomada N , Almeida H , Neves D. Energy restriction and exercise modulate Angiopoietins and Vascular Endothelial Growth Factor expression in the cavernous tissue of high-fat diet-fed rats. Asian J Androl 2012;14:635-642.
114. Tomada I , Fernandes D , Guimares JT , Almeida H , Neves D. Energy restriction ameliorates Metabolic Syndrome-induced cavernous tissue structural modifi cations in aged rats. Age (Dordr) 2012 [Epub ahead of print].
115. Maio MT , Hannan JL , Komolova M , Adams MA. Caloric restriction prevents visceral adipose tissue accumulation and maintains erectile function in aging rats. J Sex Med 2012;9:2273-2283.
116. Sakata N , Imanaga Y , Meng J , Tachikawa Y , Takebayashi S , Nagai R , et al. Immunohistochemical localization of diff erent epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998;141:61-75.
117. Woods TM , Kamalov M , Harris PW , Cooper GJ , Brimble M. Synthesis of monolysyl advanced glycation endproducts and their incorporation into collagen model peptides. Org Lett 2012;14:5740-5743.
118. Sell DR , Lane MA , Obrenovich ME , Mattison JA , Handy A , Ingram DK, et al. The Effect of caloric restriction on glycation and glycoxidation in skin collagen of nonhuman primates. J Gerontol Biol Sci 2003;58A:508-516.
119. Azadzoi KM , Schulman RN , Aviram M , Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J Urol 2005;174:386-393.
120. Zhang Q , Radisavljevic ZM , Siroky MB , Azadzoi KM. Dietary antioxidants improve arteriogenic erectile dysfunction. Int J Androl 2011;34:225-235.
121. Ha US , Koh JS , Kim HS , Woo JC , Kim SJ , Jang H , et al. Cyanidin-3-O-?-D-glucopyranoside concentrated materials from mulberry fruit have a potency to protect erectile function by minimizing oxidative stress in a rat model of diabetic erectile dysfunction. Urol Int 2012;88:470-476.
122. Forest CP , Padma-Nathan H , Liker HR. Effi cacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res 2007; 19: 564-567.
123. Achike FI , Kwan CY. Nitric oxide, human diseases and the herbal products that aff ect the nitric oxide signalling pathway. Clin Exp Pharmacol Physiol 2003;30:605-615.
124. McCann SM , Licinio J , Wong ML , Yu WH , Karanth S , Rettorri V. The nitric oxide hypothesis of aging. Exp Gerontol 1998; 33: 813-826.
125. Neves D , Tomada I , Assun?o M , Marques F , Almeida H , Andrade JP. Effects of chronic red wine consumption on the expression of vascular endothelial growth factor, angiopoietin 1, angiopoietin 2 and its receptors in rat erectile tissue. J Food Science 2010; 75: H79-H86.
126. Lima CF , Pereira-Wilson C , Rattan SI. Curcumin induces heme oxygenase-1 in normal human skin fi broblasts through redox signaling: relevance for anti-Aging intervention. Mol Nutr Food Res 2011; 55: 430-442.
127. Shen LR , Xiao F , Yuan P , Chen Y , Gao QK , Parnell LD et al. Curcumin-supplemented diets increase superoxide dismutase activity and mean lifespan in Drosophila. Age (Dordr) 2012 [Epub ahead of print].
128. Hu TY , Liu CL , Chyau CC , Hu ML. Trapping of methylglyoxal by curcumin in cell-free systems and in human umbilical vein endothelial cells. J Agric Food Chem 2012;60:8190-8196.
129. Lin J , Tang Y , Kang Q , Feng Y , Chen A. Curcumin inhibits gene expression of receptor for advanced glycation endproducts (RAGE) in hepatic stellate cells in vitro by elevating PPAR?activity and attenuating oxidative stress. Br J Pharmacol 2012;166:2212-2227.
130. Lin J , Tang Y , Kang Q , Chen A. Curcumin eliminates the inhibitory Effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest 2012;92:827-841.
131. Yang Q , Wu S , Mao X , Wang W , Tai H. Inhibition Effect of curcumin on TNF-and MMP-13 expression induced by advanced glycation end products in chondrocytes. Pharmacology 2013;91:77-85.
132. Pendurthi UR , Williams JT , Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol. 1997;17:3406-3413.
133. Bierhaus A , Zhang Y , Quehenberger P , Luther T , Haase M , M?ler M et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997;77:772-782.
134. Olszanecki R , Gebska A , Korbut R. The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin. Basic Clin Pharmacol Toxicol. 2007;101:411-415.
135. Binion DG , Heidemann J , Li MS , Nelson VM , Otterson MF , Rafi ee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol. 2009;297:G259-268.
136. Panicker SR , Kartha CC. Curcumin attenuates glucoseinduced monocyte chemoattractant protein-1 synthesis in aortic endothelial cells by modulating the nuclear factorkappaB pathway. Pharmacology 2010;85:18-26.
137. Kumar A , Dhawan S , Hardegen NJ , Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol. 1998;55:775-783.
138. Bae MK , Kim SH , Jeong JW , Lee YM , Kim HS , Kim SR et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006;15:1557-1562.
139. Chen YR , Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998;17:173-178.
140. Akhand AA , Hossain K , Mitsui H , Kato M , Miyata T , Inagi R et al. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 2001; 31: 20-30.
141. Kim DC , Lee W , Bae JS. Vascular anti-infl ammatory Effects of curcumin on HMGB1-mediated responses in vitro. Infl amm Res 2011;60:1161-1168.
142. Han J , Pan XY , Xu Y , Xiao Y , An Y , Tie L et al. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 2012; 8: 812-825.
143. Bradford PG. Curcumin and obesity. Biofactors 2013;39:78-87.
144. Yang Y , Duan W , Liang Z , Yi W , Yan J , Wang N et al. Curcumin attenuates endothelial cell oxidative stress injury through Notch signaling inhibition. Cell Signal 2013;25:615-629.
145. Yu YM , Lin HC. Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis 2010;20:125-132.
146. Chen HW , Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998;124:1029-1040.
147. Pae HO , Jeong GS , Jeong SO , Kim HS , Kim SA , Kim YC , et al. Roles of heme oxygenase-1 in curcumin-induced growth inhibition in rat smooth muscle cells. Exp Mol Med 2007;39:267-277.
148. Youreva V , Kapakos G , Srivastava AK. Insulin-like growthfactor-1- induced PKB signaling and Egr-1 expression is inhibited by curcumin in A-10 vascular smooth muscle cells. Can J Physiol Pharmacol 2013;91:241-247.
149. Yang X , Thomas DP , Zhang X , Culver BW , Alexander BM , Murdoch WJ, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006;26:85-90.
150. Hua Y , Dolence J , Ramanan S , Ren J , Nair S. Bisdemethoxycurcumin inhibits PDGF-induced vascular smooth muscle cell motility and proliferation. Mol Nutr Food Res 2013 [Epub ahead of print].
151. Kang ES , Woo IS , Kim HJ , Eun SY , Paek KS , Kim HJ , et al. Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective Effect of curcumin against oxidative damage. Free Radic Biol Med 2007; 43: 535-545.
152. Meng Z , Yan C , Deng Q , Gao DF , Niu XL. Curcumin inhibits LPS-induced Inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-B pathways. Acta Pharmacol Sin 2013 [Epub ahead of print].
153. Kapakos G , Youreva V , Srivastava AK. Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells. Can J Physiol Pharmacol 2012;90:1277-1285.
154. Fleenor BS , Sindler AL , Marvi NK , Howell KL , Zigler ML , Yoshizawa M, Seals DR. Curcumin ameliorates arterial dysfunction and oxidative stress with aging. Exp Gerontol 2012 [Epub ahead of print].
155. Majithiya JB , Balaraman R. Time-dependent changes in antioxidant enzymes and vascular reactivity of aorta in streptozotocin-induced diabetic rats treated with curcumin. J Cardiovasc Pharmacol 2005;46:697-705.
156. Nakmareong S , Kukongviriyapan U , Pakdeechote P , Kukongviriyapan V , Kongyingyoes B , Donpunha W , et al. Tetrahydrocurcumin alleviates hypertension, aortic stiff ening and oxidative stress in rats with nitric oxide defi ciency. Hypertens Res 2012;35:418-425.
157. Rungseesantivanon S , Thenchaisri N , Ruangvejvorachai P , Patumraj S. Curcumin supplementation could improve diabetes-induced endothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complement Altern Med 2010; 10: 57.
158. Coban D , Milenkovic D , Chanet A , Khallou-Laschet J , Sabbe L, Palagani A, et al. Dietary curcumin inhibits atherosclerosis by aff ecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res 2012; 56: 1270-1281.
159. Sajithlal GB , Chithra P , Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 1998;56:1607-1614.
160. Abdel Aziz MT , Motawi T , Rezq A , Mostafa T , Fouad HH , Ahmed HH , et al. Effects of a water-soluble curcumin protein conjugate vs. pure curcumin in a diabetic model of erectile dysfunction. J Sex Med 2012;9:1815-1833.
161. Farhangkhoee H , Khan ZA , Chen S , Chakrabarti S. Differential Effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab 2006;183:27.
162. Margina D , Gradinaru D , Manda G , Neagoe I , Ilie M. Membranar Effects exerted in vitro by polyphenols-quercetin, epigallocatechin gallate and curcumin-on HUVEC and Jurkat cells, relevant for diabetes mellitus. Food Chem Toxicol 2013 [Epub ahead of print].
163. Mizutani K , Ikeda K , Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000;274:61-67.
164. Babu PV , Sabitha KE , Srinivasan P , Shyamaladevi CS. Green tea attenuates diabetes induced Maillard-type fl uorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res 2007;55:433-40.
165. Rajasekar P , Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol 2007;44:83-90.
166. Cavallini G , Caracciolo S , Vitali G , Modenini F , Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641-646.
167. Gianfrilli D , Lauretta R , Di Dato C , Graziadio C , Pozza C , De Larichaudy J , et al. Propionyl-L-carnitine, L-Arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. Andrologia 2012;44:600-604.
168. Cavallini G , Modenini F , Vitali G , Koverech A. Acetyl-Lcarnitine plus propionyl-L-carnitine improve effi cacy of sildenafi l in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005;66:1080-1085.
169. Gentile V , Vicini P , Prigiotti G , Koverech A , Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafi l in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-1384.
170. Gentile V , Antonini G , Antonella Bertozzi M , Dinelli N , Rizzo C, Ashraf Virmani M, Koverech A. Effect of propionyl-L-carnitine, L-Arginine and nicotinic acid on the effi cacy of vardenafi l in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin 2009;25:2223-2228.
171. Morano S , Mandosi E , Fallarino M , Gatti A , Tiberti C , Sensi M , et al. Antioxidant treatment associated with sildenafi l reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007;52:1768-1774.
172. Booth AA , Khalifah RG , Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996;220:113-119.
173. Avena R , Arora S , Carmody BJ , Cosby K , Sidawy NA. Thiamine (Vitamin B1) protects against glucose-And insulinmediated proliferation of human infragenicular arterial smooth muscle cells. Ann Vasc Surg 2000;14:37-43.
174. Beltramo E , Berrone E , Buttiglieri S , Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20:330-336.
175. Alkhalaf A , Kleefstra N , Groenier KH , Bilo HJ , Gans RO , Heeringa P , et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and Inflammation in diabetic nephropathy. PLoS One 2012;7:e40427.
176. Alderson NL , Chachich ME , Youssef NN , Beattie RJ , Nachtigal M , Thorpe SR , Baynes JW. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63:2123-2133.
177. Chang KC , Liang JT , Tsai PS , Wu MS , Hsu KL. Prevention of arterial stiff ening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 2009;157:1419-1426.
178. Wu ET , Liang JT , Wu MS , Chang KC. Pyridoxamine prevents age-related aortic stiff ening and vascular resistance in association with reduced collagen glycation. Exp Gerontol 2011;46:482-488.
179. Watson AM , Soro-Paavonen A , Sheehy K , Li J , Calkin AC , Koitka A, et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-Accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2011;54:681-689.
180. Jain SK , Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na-K-)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001;30:232-237.
181. Giannoukakis N. Pyridoxamine (BioStratum). Curr Opin Investig Drugs 2005;6:410-418.
182. Lewis EJ , Greene T , Spitalewiz S , Blumenthal S , Berl T , Hunsicker LG , et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:131-136.
183. Williams ME , Bolton WK , Khalifah RG , Degenhardt TP , Schotzinger RJ , McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27:605-614.
184. Bierhaus A , Chevion S , Chevion M , Hofmann M , Quehenberger P , Illmer T , et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-1490.
185. Keegan A , Cotter MA , Cameron NE. Corpus cavernosum dysfunction in diabetic rats: Effects of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001;17:380-386.
186. Hipkiss AR. Carnosine and its possible roles in nutrition and health. Adv Food Nutr Res 2009; 57: 87-154.
187. Krajcovicov-KudlckovM , SebekovK , Schinzel R , KlvanovJ. Advanced glycation end products and nutrition. Physiol Res 2002;51:313-316.
188. Li YM , Tan AX , Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modifi ed proteins to a conserved motif. Nat Med 1995;1:1057-1061.
189. Tan D , Wang Y , Lo CY , Sang S , Ho CT. Methylglyoxal: its presence in beverages and potential scavengers. Ann N Y Acad Sci 2008;1126:72-75.
190. Ruhs S , Nass N , Somoza V , Friess U , Schinzel R , Silber RE , Simm A. Maillard reaction products enriched food extract reduce the expression of myofi broblast phenotype markers. Mol Nutr Food Res 2007; 51: 488-495.
191. Leuner B , Ruhs S , Brmme HJ , Bierhaus A , Sel S , Silber RE , et al. RAGE-dependent activation of gene expression of superoxide dismutase and vanins by AGE-rich extracts in mice cardiac tissue and murine cardiac fi broblasts. Food Funct 2012; 3: 1091-1098.
192. Ruhs S , Nass N , Bartling B , Brmme HJ , Leuner B , Somoza V , et al. Preconditioning with Maillard reaction products improves antioxidant defence leading to increased stress tolerance in cardiac cells. Exp Gerontol 2010;45:752-762.
193. Anton PM , Craus A , Niquet-Lridon C , Tessier FJ. Highly heated food rich in Maillard reaction products limit an experimental colitis in mice. Food Funct 2012; 3: 941-949
194. Niebauer J , Maxwell AJ , Lin PS , Wang D , Tsao PS , Cooke JP. NOS inhibition accelerates atherogenesis: reversal by exercise. Am J Physiol Heart Circ Physiol 2003;285:H535-H540.
195. Esposito K , Giugliano F , Di Palo C , Giugliano G , Marfella R, D' Andrea F , et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978-2984.
196. Boor P , Celec P , Behuliak M , Grancic P , Kebis A , Kukan M , et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58:1669-1677.
197. Choi KM , Han KA , Ahn HJ , Hwang SY , Hong HC , Choi HY , et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:3751-3758.
198. Kotani K , Caccavello R , Sakane N , Yamada T , Taniguchi N , Gugliucci A. Influence of physical activity intervention on circulating soluble receptor for advanced glycation end products in elderly subjects. J Clin Med Res 2011;3:252-257.
199. Lu J , Gong D , Choong SY , Xu H , Chan YK , Chen X , et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010;53:1217-1226.
200. Koupparis AJ , Jeremy J , Angelini G , Persad R , Shukla N. Penicillamine administration reverses the inhibitory Effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. BJU Int 2006;98:440-444.
201. Keegan A , Cotter MA , Cameron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radic Biol Med 1999; 27: 536-543.
202. Gur S , Kadowitz PJ , Hellstrom WJ. A critical appraisal of erectile function in animal models of diabetes mellitus. Int J Androl 2009;32:93-114.
203. Vlassara H , Bucala R , Striker L. Pathogenic Effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-151.
204. Ihm SH , Yoo HJ , Park SW , Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999;48:1141-1145.
205. SzabC , Ferrer-Sueta G , Zingarelli B , Southan GJ , Salzman AL, Radi R. Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 1997;272:9030-9036.
206. Price DL , Rhett PM , Thorpe SR , Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001;276:48967-48972.
207. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31-40.
208. Brownlee M , Vlassara H , Kooney A , Ulrich P , Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-1632.
209. Sell DR , Nelson JF , Monnier VM. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol A Biol Sci Med Sci 2001;56:B405-B411.
210. Griffi ths MJ , Messent M , MacAllister RJ , Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963-968.
211. Misko TP , Moore WM , Kasten TP , Nickols GA , Corbett JA , Tilton RG , et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-125.
212. Wessells H , Teal TH , Luttrell IP , Sullivan CJ. Effect of endothelial cell-based iNOS gene transfer on cavernosal eNOS expression and mouse erectile responses. Int J Impot Res 2006;18:438-445.
213. Usta MF , Bivalacqua TJ , Yang DY , Ramanitharan A , Sell DR, Viswanathan A, et al. The protective Effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003;170:1437-1442.
214. Usta MF , Bivalacqua TJ , Koksal IT , Toptas B , Surmen S , Hellstrom WJ. The protective Effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int 2004;94:429-432.
215. Forbes JM , Yee LT , Thallas V , Lassila M , Candido R , Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-Accelerated atherosclerosis. Diabetes 2004;53:1813-1823.
216. Asif M , Egan J , Vasan S , Jyothirmayi GN , Masurekar MR , Lopez S , et al. An advanced glycation end product cross-link breaker can reverse age-related increases in myocardial stiff-ness. Proc Natl Acad Sci USA 2000;97:2809-2813.
217. Usta MF , Kendirci M , Gur S , Foxwell NA , Bivalacqua TJ , Cellek S, Hellstrom WJ. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 242-250.
218. Gurbuz N , Sagdic G , Sanli A , Ciftcioglu A , Bassorgun I , Baykal A, Usta MF. Therapeutic Effect of combination of alagebrium (ALT-711) and sildenafi l on erectile function in diabetic rats. Int J Impot Res 2012; 24: 114-121.
219. Hartog JW , Willemsen S , van Veldhuisen DJ , Posma JL , van Wijk LM , Hummel YM , et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011;13:899-908.
220. Wiernsperger NF , Bailey CJ. The antihyperglycaemic Effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58:31-39.
221. Paolisso G , Amato L , Eccellente R , Gambardella A , Tagliamonte MR, Varricchio G, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998;28:441-446.
222. Seifarth C , Schehler B , Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2012 [Epub ahead of print].
223. Beisswenger PA , Howell SK , Touchette AD , Lal S , Szwergold BS. Metformin reduces systematic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198-202.
224. Beisswenger P , Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 6S95-103.
225. Chakraborty A , Chowdhury S , Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and infl ammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011; 93: 56-62.
226. Kim YW , Park SY , Kim JY , Huh JY , Jeon WS , Yoon CJ , et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl 2007;28:555-560.
227. Rey-Valzacchi GJ , Costanzo PR , Finger LA , Layus AO , Gueglio GM , Litwak LE , Knoblovits P. Addition of metformin to sildenafi l treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study. J Androl 2012;33:608-614.
228. Rahbar S , Natarajan R , Yerneni K , Scott S , Gonzales N , Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000;301:65-77.
229. Kovanecz I , Ferrini MG , Vernet D , Nolazco G , Rajfer J , Gonzalez-Cadavid NF. Pioglitazone prevents corporal venoocclusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006;98:116-124.
230. Kovanecz I , Ferrini MG , Vernet D , Nolazco G , Rajfer J , Gonzalez-Cadavid NF. Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int 2007;100:867-874.
231. Gholamine B , Shafi ei M , Motevallian M , Mahmoudian M. Effects of pioglitazone on erectile dysfunction in sildenafi l poor-responders: a randomized, controlled study. J Pharm Pharm Sci 2008;11:22-31.
232. Ishibashi Y , Matsui T , Takeuchi M , Yamagishi S. Vardenafi l, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced upregulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med 2011;11:131-135.
233. Ridker PM , Danielson E , Fonseca FA , Genest J , Gotto AM Jr, Kastelein JJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
234. de Vries FM , Denig P , Pouwels KB , Postma MJ , Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-Analysis. Drugs 2012;72:2365-2373.
235. Long SB , Blaha MJ , Blumenthal RS , Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging 2011;6:27-35.
236. Antonopoulos AS , Margaritis M , Shirodaria C , Antoniades C. Translating the Effects of statins: From redox regulation to suppression of vascular wall Inflammation. Thromb Haemost 2012;108:840-848.
237. Balakumar P , Kathuria S , Taneja G , Kalra S , Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins J Mol Cell Cardiol 2012;52:83-92.
238. Ishida K , Matsumoto T , Taguchi K , Kamata K , Kobayashi T. Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat. Acta Physiol 2012;205:255-265.
239. Okamoto T , Yamagishi S , Inagaki Y , Amano S , Koga K , Abe R , et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-1930.
240. Santilli F , Bucciarelli L , Noto D , CefalAB , DavV , Ferrante E , et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. Free Radic Biol Med 2007;43:1255-1262.
241. Tam HL , Shiu SW , Wong Y , Chow WS , Betteridge DJ , Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010;209:173-177.
242. Jinnouchi Y , Yamagishi S , Takeuchi M , Ishida S , Jinnouchi Y , Jinnouchi J, Imaizumi T. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191-193.
243. Mahajan N , Bahl A , Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its infl ammatory ligand EN-RAGE in THP-1 cells: inhibitory Effects of atorvastatin. Int J Cardiol 2010;142:273-278.
244. Yoon SJ , Yoon YW , Lee BK , Kwon HM , Hwang KC , Kim M , et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009;41:802-811.
245. Feng B , Xu L , Wang H , Yan X , Xue J , Liu F , Hu JF. Atorvastatin exerts its anti-Atherosclerotic Effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta 2011;1812:1130-1137.
246. Saltzman EA , Guay AT , Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004;172:255-258.
247. Rizvi K , Hampson JP , Harvey JN. Do lipid-lowering drugs cause erectile dysfunction A systematic review. Fam Pract 2002;19:95-98.
248. Trivedi D , Kirby M , Wellsted DM , Ali S , Hackett G , O'Connor B, van Os S. Can simvastatin improve erectile function and health-related quality of life in men aged-40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2012 [Epub ahead of print].
249. Castro MM , Rizzi E , Rascado RR , Nagassaki S , Bendhack LM , Tanus-Santos JE. Atorvastatin enhances sildenafi l-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004;498:189-194.
250. Dadkhah F , Safarinejad MR , Asgari MA , Hosseini SY , Lashay A, Amini E. Atorvastatin improves the response to sildenafi l in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafi l. Int J Impot Res 2010;22:51-60.
251. Herrmann HC , Levine LA , Macaluso J Jr, Walsh M , Bradbury D, Schwartz S, et al. Can atorvastatin improve the response to sildenafi l in men with erectile dysfunction not initially responsive to sildenafi l? Hypothesis and pilot trial results. J Sex Med 2006;3:303-308.
252. Bank AJ , Kelly AS , Kaiser DR , Crawford WW , Waxman B , Schow DA , Billups KL. The Effects of quinapril and atorvastatin on the responsiveness to sildenafi l in men with erectile dysfunction. Vasc Med 2006;11:251-257.
253. Fibbi B , Morelli A , Marini M , Zhang XH , Mancina R , Vignozzi L, et al. Atorvastatin but not elocalcitol increases sildenafi l responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 2008;29:70-84.
254. Forbes JM , Thorpe SR , Thallas-Bonke V , Pete J , Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-2372.
255. Schlimmer N , Kratz M , Bhm M , Baumhkel M. Telmisartan, ramipril and their combination improve endothelial function in diff erent tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 2011;163:804-814.
256. Bhm M , Baumhkel M , Teo K , Sleight P , Probstfi eld J , Gao P , et al.; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010;121:1439-1446.
257. Simm A , Wagner J , Gursinsky T , Nass N , Friedrich I , Schinzel R, et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 2007; 42: 668-675.
258. Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002;14:178-188.
259. Kloner RA , Henderson L. Sexual function in patients with chronic angina pectoris. Am J Cardiol 2013 [Epub ahead of print].
260. Timmis AD , Chaitman BR , Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-48.